Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Romiplostim

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Romiplostim: Patents, clinical trial progress, indications

Romiplostim is an investigational drug.

There have been 30 clinical trials for Romiplostim. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2016.

The most common disease conditions in clinical trials are Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, and Preleukemia. The leading clinical trial sponsors are Amgen, Kyowa Hakko Kirin China Pharmaceutical Co.,LTD., and Assistance Publique - Hôpitaux de Paris.

There are eight hundred and seventeen US patents protecting this investigational drug and eight international patents.

Recent Clinical Trials for Romiplostim
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerAmgenPhase 3
Study of AMG531 (Romiplostim) in Patients With Aplastic AnemiaKyowa Kirin Co., Ltd.Phase 2/Phase 3
Study of AMG531(Romiplostim) in Patients With Aplastic AnemiaKyowa Hakko Kirin Co., LtdPhase 2/Phase 3

See all Romiplostim clinical trials

Clinical Trial Summary for Romiplostim

Top disease conditions for Romiplostim
Top clinical trial sponsors for Romiplostim

See all Romiplostim clinical trials

US Patents for Romiplostim

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Romiplostim   See Pricing Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   See Pricing
Romiplostim   See Pricing ALK and NTRK1 fusion molecules and uses thereof FOUNDATION MEDICINE, INC. (Cambridge, MA)   See Pricing
Romiplostim   See Pricing B7 family member zB7H6 and related compositions and methods Zymogenetics, Inc. (Princeton, NJ)   See Pricing
Romiplostim   See Pricing Trilayer coated pharmaceutical packaging SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Romiplostim

Drugname Country Document Number Estimated Expiration Related US Patent
Romiplostim Australia 2015231053 2034-03-21   See Pricing
Romiplostim Brazil 112016021620 2034-03-21   See Pricing
Romiplostim Canada 2943339 2034-03-21   See Pricing
Romiplostim China 106231900 2034-03-21   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.